Fig. 7. BAFF-R demonstrates potent anti-tumor in vivo activity in solid and hematological cancers.

(A) Tumors were untreated, treated with untransduced T cells, or treated with engineered CAR T cells. Tumor size was monitored over 49 days post tumor injection. CAR T cells containing the potent costimulatory domains are shown, compared to untransduced T cells and no T cell controls. Data are representative of 5 in vivo experiments using 2 human donors. (B) Tumor size as in (A), showing a CD3ζ-only control and a KLRG1 inhibitory CAR, compared to untransduced T cells and no T cells. Error bars in (A and B) indicate standard error of the mean for tumor volumes across mice with the same treatment. (C) MM1S cancer radiance after luciferin injection was plotted over time for individual mice across CAR T cells generated from two donors. Tumors were measured by BLI every 7 days for a total of over 30 days. This was repeated independently in two donors. For panels (A to C), statistical analysis was done by t test on the normalized tumor volume area under the curve (AUC). (D) Survival curves are shown mice with MM1S cancer using T cells from a representative donor; mice were followed past 100 days (Mantel Cox test). For all panels, p<0.05:*, p<0.01:**, p<0.0001:****; ns, not significant.